Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: A putative model of gene×environment interaction

Brain, Behavior, and Immunity

Volumn 26, Issue 4, 2012, Pages 660-671

  Desbonnet, Lieve ^a   O'Tuathaigh, Colm ^a,b   Clarke, Gerard ^c,d   O'Leary, Claire ^a   Petit, Emilie ^a   Clarke, Niamh ^a   Tighe, Orna ^a   Lai, Donna ^e   Harvey, Richard ^e   Cryan, John F ^c,d   Dinan, Timothy G ^c,d   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Behavioural phenotype; Concanavalin A; Cytokines; Gene environment interaction; Lipopolysaccharide; Neuregulin 1; Prepulse inhibition; Schizophrenia; Social defeat stress; Working memory

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CONCANAVALIN A; CORTICOSTERONE; CYTOKINE; KYNURENIC ACID; KYNURENINE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGENIC AGENT; NEU DIFFERENTIATION FACTOR; SUCROSE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CHRONIC SOCIAL DEFEAT; CONTROLLED STUDY; CORPUS STRIATUM; EXPLORATORY BEHAVIOR; FRONTAL CORTEX; GENE DELETION; GENOTYPE ENVIRONMENT INTERACTION; HIPPOCAMPUS; HYPERACTIVITY; MALE; MENTAL STRESS; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL STRESS; SPATIAL MEMORY; SPLEEN; SPLEEN CELL; WORKING MEMORY;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CYTOKINES; DISEASE MODELS, ANIMAL; ENVIRONMENT; EXPLORATORY BEHAVIOR; GENE-ENVIRONMENT INTERACTION; GENOTYPE; MICE; MICE, KNOCKOUT; NEUREGULIN-1; PHENOTYPE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 84859425428     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.02.010     Document Type: Article

References (86)

1. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40:827-834.
2. Almli C.R., Levy T.J., Han B.H., Shah A.R., Gidday J.M., Holtzman D.M. BDNF protects against spatial memory deficits following neonatal hypoxia-ischemia. Exp. Neurol. 2000, 166:99-114.
3. Audet M.C., Jacobson-Pick S., Wann B.P., Anisman H. Social defeat promotes specific cytokine variations within the prefrontal cortex upon subsequent aggressive or endotoxin challenges. Brain Behav. Immun. 2011, 25:1197-1205.
4. Ayhan Y., Sawa A., Ross C.A., Pletnikov M.V. Animal models of gene-environment interactions in schizophrenia. Behav. Brain Res. 2009, 204:274-281.
5. Avgustinovich D.F., Kovalenko I.L., Kudryavtseva N.N. A model of anxious depression: persistence of behavioral pathology. Neurosci. Behav. Physiol. 2005, 35:917-924.
6. Avitsur R., Stark J.L., Dhabhar F.S., Sheridan J.F. Social stress alters splenocyte phenotype and function. J. Neuroimmunol. 2002, 132:66-71.
7. Bailey M.T., Avitsur R., Engler H., Padgett D.A., Sheridan J.F. Physical defeat reduces the sensitivity of murine splenocytes to the suppressive effects of corticosterone. Brain Behav. Immun. 2004, 18:416-424.
8. Balu D.T., Coyle J.T. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci. Biobehav. Rev. 2011, 35:848-870.
9. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., Graham D., Tsankova N.M., Bolanos C.A., Rios M., Monteggia L.M., Self D.W., Nestler E.J. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311:864-868.
10. Bertram L. Genetic research in schizophrenia: new tools and future perspectives. Schizophr. Bull. 2008, 34:806-812.
11. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001, 156:234-258.
12. Böer U., Cierny I., Krause D., Heinrich A., Lin H., Mayr G., Hiemke C., Knepel W. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacology 2008, 33:2407-2415.
13. Bora E., Yucel M., Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br. J. Psychiatry 2009, 195:475-482.
14. Boucher A.A., Hunt G.E., Karl T., Micheau J., McGregor I.S., Arnold J.C. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007, 149:861-870.
15. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology 2007, 192:325-336.
16. Boucher A.A., Hunt G.E., Micheau J., Huang X., McGregor I.S., Karl T., Arnold J.C. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int. J. Neuropsychopharmacol. 2010, 12:1-13.
17. Bowens N., Heydendael W., Bhatnagar S., Jacobson L. Lack of elevations in glucocorticoids correlates with dysphoria-like behavior after repeated social defeat. Physiol. Behav. 2011, 105:958-965.
18. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotrophic factor in first-episode psychosis. Schizophr. Res. 2007, 91:1-5.
19. Chesworth R., Downey L., Logge W., Killcross S., Karl T. Cognition in female transmembrane domain neuregulin 1 mutant mice. Behav. Brain Res. 2012, 226:218-223.
20. Coppens C.M., Siripornmongcolchai T., Wibrand K., Alme M.N., Buwalda B., de Boer S.F., Koolhaas J.M., Bramham C.R. Social defeat during adolescence and adulthood differentially induce BDNF-regulated immediate early genes. Front Behav. Neurosci. 2011, 5:72.
21. Curtin N.M., Boyle N.T., Mills K.H., Connor T.J. Psychological stress suppresses innate IFN-gamma production via glucocorticoid receptor activation: reversal by the anxiolytic chlordiazepoxide. Brain Behav. Immun. 2009, 23:535-547.
22. Desbonnet L., Garrett L., Clarke G., Bienenstock J., Dinan T.G. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J. Psychiatr. Res. 2008, 43:164-174.
23. Desbonnet L., Waddington J.L., Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. Behav. Brain Res. 2009, 204:258-273.
24. Desbonnet L., Tighe O., Karayiorgou M., Gogos J.A., Waddington J.L., O'Tuathaigh C.M. Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice. Behav. Brain Res 2012, 228:351-358.
25. Duffy L., Cappas E., Lai D., Boucher A.A., Karl T. Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 2010, 170:800-807.
26. Fan X., Goff D.C., Henderson D.C. Inflammation and schizophrenia. Expert Rev. Neurother. 2007, 7:789-796.
27. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. J. Psychiatr. Res. 2012, 46:1-11.
28. García-Bueno B., Leza J.C. Inflammatory/anti-inflammatory mechanisms in the brain following exposure to stress. Rev. Neurol. 2008, 46:675-683.
29. Gill M., Donohoe G., Corvin A. What have the genomics ever done for the psychoses?. Psychol. Med. 2010, 40:529-540.
30. Hänsel A., Hong S., Cámara R.J., von Känel R. Inflammation as a psychophysiological biomarker in chronic psychosocial stress. Neurosci. Biobehav. Rev. 2010, 35:115-121.
31. Hazeki K., Nigorikawa K., Hazeki O. Role of phosphoinositide 3-kinase in innate immunity. Biol. Pharm. Bull. 2007, 30:1617-1623.
32. Jacobson-Pick S., Audet M.C., Nathoo N., Anisman H. Stressor experiences during the juvenile period increase stressor responsivity in adulthood: transmission of stressor experiences. Behav. Brain Res. 2011, 216:365-374.
33. Joëls M., de Kloet E.R. Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter systems. Prog. Neurobiol. 1994, 43:1-36.
34. Jones S.R., Fernyhough C. A new look at the neural diathesis-stress model of schizophrenia: the primacy of social-evaluative and uncontrollable situations. Schizophr. Bull. 2007, 33:1171-1177.
35. Kalkman H.O. Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia. Pharmacol. Ther. 2009, 121:115-122.
36. Karl T., Burne T.H., Van den Buuse M., Chesworth R. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. Behav. Brain Res. 2011, 223:336-341.
37. Kelly B.D., O'Callaghan E., Waddington J.L., Feeney L., Browne S., Scully P.J., Clarke M., Quinn J.F., McTigue O., Morgan M.G., Kinsella A., Larkin C. Schizophrenia and the city: a review of literature and prospective study of psychosis and urbanicity in Ireland. Schizophr. Res. 2010, 116:75-89.
38. Kéri S., Kiss I., Seres I., Kelemen O. A polymorphism of the neuregulin 1 gene (SNP8NRG243177/rs6994992) affects reactivity to expressed emotion in schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2009, 150:418-420.
39. Kéri S., Beniczky S., Kelemen O. Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia. Am. J. Psychiatry 2010, 167:444-450.
40. Kirby B.P., Waddington J.L., O'Tuathaigh C.M. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res. Bull. 2010, 83:162-176.
41. Kirkbride J., Coid J.W., Morgan C., Fearon P., Dazzan P., Yang M., Lloyd T., Harrison G.L., Murray R.M., Jones P.B. Translating the epidemiology of psychosis into public mental health: evidence, challenges and future prospects. J. Public Ment. Health 2010, 9:4-14.
42. Krishnan V., Han M.H., Graham D.L., Berton O., Renthal W., Russo S.J., Laplant Q., Graham A., Lutter M., Lagace D.C., Ghose S., Reister R., Tannous P., Green T.A., Neve R.L., Chakravarty S., Kumar A., Eisch A.J., Self D.W., Lee F.S., Tamminga C.A., Cooper D.C., Gershenfeld H.K., Nestler E.J. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
43. Krishnan V., Han M.H., Mazei-Robison M., Iñiguez S.D., Ables J.L., Vialou V., Berton O., Ghose S., Covington H.E., Wiley M.D., Henderson R.P., Neve R.L., Eisch A.J., Tamminga C.A., Russo S.J., Bolaños C.A., Nestler E.J. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol. Psychiatry 2008, 64:691-700.
44. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
45. Maes M. Cytokines in major depression. Biol. Psychiatry 1994, 36:498-499.
46. Marballi K., Quinones M.P., Jimenez F., Escamilla M.A., Raventós H., Soto-Bernardini M.C., Ahuja S.S., Walss-Bass C. In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation. J. Mol. Med. 2010, 88:1133-1141.
47. Mays J.W., Bailey M.T., Hunzeker J.T., Powell N.D., Papenfuss T., Karlsson E.A., Padgett D.A., Sheridan J.F. Influenza virus-specific immunological memory is enhanced by repeated social defeat. J. Immunol. 2010, 184:2014-2025.
48. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
49. Merlot E., Moze E., Dantzer R., Neveu P.J. Cytokine production by spleen cells after social defeat in mice. activation of T cells and reduced inhibition by glucocorticoids. Stress 2004, 7:55-61.
50. Miczek K.A., Thompson M.L., Shuster L. Opioid-like analgesia in defeated mice. Science 1982, 215:1520-1522.
51. Müller N., Myint A.M., Schwarz M.J. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr. Pharm. Des. 2011, 17:130-136.
52. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., Young N.B., Barbaro R.P., Piven J., Magnuson T.R., Crawley J.N. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 2004, 3:303-314.
53. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., Waddington J.L. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. NeuroReport 2006, 17:79-83.
54. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., Harvey R., Waddington J.L. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007, 147:18-27.
55. O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Lai D., Harvey R., Croke D.T., Waddington J.L. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:462-466.
56. O'Tuathaigh C.M., Harte M., O'Leary C., O'Sullivan G.J., Blau C., Lai D., Harvey R.P., Tighe O., Fagan A.J., Kerskens C., Reynolds G.P., Waddington J.L. Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur. J. Neurosci. 2010, 31:349-358.
57. O'Tuathaigh C.M., Desbonnet L., Moran P.M., Kirby B.P., Waddington J.L. Molecular genetic models related to schizophrenia and psychotic illness: heuristics and challenges. Curr. Top. Behav. Neurosci. 2011, 7:87-119.
58. O'Tuathaigh C.M., Clarke G., Walsh J., Desbonnet L., Petit E., O'Leary C., Tighe O., Clarke N., Karayiorgou M., Gogos J.A., Dinan T.G., Cryan J.F., Waddington J.L. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int. J. Neuropsychopharmacol. 2011, 11:1-12.
59. Owen M.J., Craddock N., O'Donovan M.C. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch. Gen. Psychiatry 2010, 67:667-673.
60. Paul E.D., Hale M.W., Lukkes J.L., Valentine M.J., Sarchet D.M., Lowry C.A. Repeated social defeat increases reactive emotional coping behavior and alters functional responses in serotonergic neurons in the rat dorsal raphe nucleus. Physiol. Behav. 2011, 104:272-282.
61. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
62. Powell N.D., Bailey M.T., Mays J.W., Stiner-Jones L.M., Hanke M.L., Padgett D.A., Sheridan J.F. Repeated social defeat activates dendritic cells and enhances Toll-like receptor dependent cytokine secretion. Brain Behav. Immun. 2009, 23:225-231.
63. Reichenberg A., Harvey P.D. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychol. Bull. 2007, 133:833-858.
64. Roussos P., Giakoumaki S.G., Adamaki E., Bitsios P. The influence of schizophrenia-related neuregulin-1 polymorphisms on sensorimotor gating in healthy males. Biol. Psychiatry 2010, 69:479-486.
65. Selten J.P., Cantor-Graae E. Social defeat: risk factor for schizophrenia?. Br. J. Psychiatry 2005, 187:101-102.
66. Selten J.P., Cantor-Graae E., Kahn R.S. Migration and schizophrenia. Curr. Opinion. Psychiatry 2007, 20:111-115.
67. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002, 71:877-892.
68. Swerdlow N.R., Braff D.L., Geyer M.A. Cross-species studies of sensorimotor gating of the startle reflex. Ann. N. Y. Acad. Sci. 1999, 877:202-216.
69. Taylor S.B., Taylor A.R., Markham J.A., Geurts A.M., Kanaskie B.Z., Koenig J.I. Disruption of the neuregulin 1 gene in the rat alters HPA axis activity and behavioral responses to environmental stimuli. Physiol. Behav. 2011, 104:205-214.
70. Tessner K.D., Mittal V., Walker E.F. Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders. Schizophr. Bull. 2011, 37:432-441.
71. van den Buuse M., Wischhof L., Lee R.X., Martin S., Karl T. Neuregulin 1 hypomorphic mutant mice. enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int. J. Neuropsychopharmacol. 2009, 12:1383-1393.
72. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice. pharmacology and methodology aspects. Schizophr. Bull. 2010, 36:246-270.
73. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
74. van Os J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 2008, 34:1066-1082.
75. van Winkel R., Stefanis N.C., Myin-Germeys I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr. Bull. 2008, 34:1095-1105.
76. van Winkel R., Esquivel G., Kenis G., Wichers M., Collip D., Peerbooms O., Rutten B., Myin-Germeys I., Van Os J. Genome-wide findings in schizophrenia and the role of gene-environment interplay. CNS Neurosci. Ther. 2010, 16:185-192.
77. Waddington J.L., Hennessy R.J., O'Tuathaigh C.M.P., Owoeye O., Russell V. Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux. The Origins of Schizophrenia 2012, 3-21. Columbia University Press, New York. A.S. Brown, P.H. Harrison (Eds.).
78. Wang X.D., Chen Y., Wolf M., Wagner K.V., Liebl C., Scharf S.H., Harbich D., Mayer B., Wurst W., Holsboer F., Deussing J.M., Baram T.Z., Müller M.B., Schmidt M.V. Forebrain CRHR1 deficiency attenuates chronic stress-induced cognitive deficits and dendritic remodeling. Neurobiol. Dis. 2011, 42:300-310.
79. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010, 64:217-230.
80. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8:592-610.
81. Wen Y., Planel E., Herman M., Figueroa H.Y., Wang L., Liu L., Lau L.F., Yu W.H., Duff K.E. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 2008, 28:2624-2632.
82. Winograd-Gurvich C., Fitzgerald P.B., Georgiou-Karistianis N., Bradshaw J.L., White O.B. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res. Bull. 2006, 70:312-321.
83. Wong J., Hyde T.M., Cassano H.L., Deep-Soboslay A., Kleinman J.E., Weickert C.S. Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 2010, 169:1071-1084.
84. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr. Bull. 2010, 36:211-218.
85. Xu Z., Ford G.D., Croslan D.R., Jiang J., Gates A., Allen R., Ford B.D. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol. Dis. 2005, 19:461-470.
86. Yu T., Guo M., Garza J., Rendon S., Sun X.L., Zhang W., Lu X.Y. Cognitive and neural correlates of depression-like behaviour in socially defeated mice: an animal model of depression with cognitive dysfunction. Int. J. Neuropsychopharmacol. 2011, 14:303-317.